BEAMing Up Personalized Medicine: Mutation Detection in Blood
Open Access
- 14 June 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (12) , 3209-3211
Abstract
BEAMing is a feasible, accurate, and sensitive method for detection of PIK3CA mutations in circulating tumor DNA in blood. Mutation status of PIK3CA may change between primary tumor and recurrence. The results suggest a new approach for noninvasive determination of current mutation status in patients with metastatic disease. Clin Cancer Res; 18(12); 3209–11. ©2012 AACR.Keywords
All Related Versions
This publication has 12 references indexed in Scilit:
- Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral BloodClinical Cancer Research, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingNew England Journal of Medicine, 2012
- Clinical trials in the era of personalized oncologyCA: A Cancer Journal for Clinicians, 2011
- A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung CancerThe Journal of Molecular Diagnostics, 2011
- Genome remodelling in a basal-like breast cancer metastasis and xenograftNature, 2010
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- BEAMing: single-molecule PCR on microparticles in water-in-oil emulsionsNature Methods, 2006
- Detection and quantification of mutations in the plasma of patients with colorectal tumorsProceedings of the National Academy of Sciences, 2005